ClinicalTrials.gov
ClinicalTrials.gov Menu

EEG Biofeedback to Improve Memory in Adults With Dementia (QMFFTD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01168466
Recruitment Status : Completed
First Posted : July 23, 2010
Last Update Posted : April 2, 2018
Sponsor:
Information provided by (Responsible Party):
Marvin H. Berman, Ph.D., Quietmind Foundation

Brief Summary:
This study measures whether the symptoms of frontotemporal dementia (FTD) can be successfully treated by (a) biofeedback training to increase brain blood flow, (b) biofeedback to increase the frequency of the brain's dominant brainwave rhythm, and (c) rhythmic stimulation to increase the brain's dominant brainwave frequency.

Condition or disease Intervention/treatment Phase
Dementia Behavioral: QEEG-based Neurofeedback Training Not Applicable

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 37 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Pilot Study of EEG and Cerebral Blood Flow Biofeedback Training in Remediating Cognitive and Behavioral Deficits in Adults With a Dementing Illness.
Study Start Date : June 2007
Actual Primary Completion Date : June 2008
Actual Study Completion Date : June 2008


Arm Intervention/treatment
No Intervention: Neurofeedback
Waitlist control group.
Experimental: QEEG-based Neurofeedback Training
A randomly selected half of participants waits 15 weeks for the other half to complete treatment, and are then reassessed, serving as controls. They then receive the same treatment as the experimental group.
Behavioral: QEEG-based Neurofeedback Training
EEG amplitude is measured and visual and auditory rewards are given when amplitude at specific locations is modified to meet preset threshholds.
Other Name: Neurofeedback



Primary Outcome Measures :
  1. Delis-Kaplan Executive Function System, Behavior Rating Inventory of Executive Function- Adult Version, Integrated Visual and Auditory Continuous Performance Test, Symptom Checklist 90R [ Time Frame: Within two weeks of last session ]
  2. EEG amplitude [ Time Frame: within two weeks of last session ]
    decreased slow wave amplitudes from 1-4hz



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   45 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

FTD Symptoms reported by self or caregiver Significantly abnormal scores on Delis-Kaplan Executive Function System and Behavior Rating Inventory of Executive Function- Adult Version

Exclusion Criteria:

  • 45 years of age
  • no one with Axis I dx of Bipolar, Psychosis or active Substance Abuse
  • no severe Axis II disorders
  • symptoms manifesting within the last 5 years and person is still somewhat independent regarding their ADLs.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01168466


Locations
United States, Pennsylvania
Quietmind Foundation
Lafayette Hill, Pennsylvania, United States, 19444-1800
Sponsors and Collaborators
Quietmind Foundation
Investigators
Principal Investigator: Marvin H Berman, Ph.D. Quietmind Foundation
Study Director: Jon Frederick, Ph.D. Quietmind Foundation

Responsible Party: Marvin H. Berman, Ph.D., President, Quietmind Foundation
ClinicalTrials.gov Identifier: NCT01168466     History of Changes
Other Study ID Numbers: QMFFTD
First Posted: July 23, 2010    Key Record Dates
Last Update Posted: April 2, 2018
Last Verified: March 2018

Keywords provided by Marvin H. Berman, Ph.D., Quietmind Foundation:
Frontotemporal Lobar Degeneration
EEG Biofeedback
Cerebral oxygenation biofeedback
Frontotemporal Dementia
Peak Alpha Amplitude
Quantitative EEG Assessment

Additional relevant MeSH terms:
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurocognitive Disorders
Mental Disorders